A more organized system is not automatically more effective
For decades, the global health system has pushed back some of humanity's oldest killers — yet the very success of that effort now strains the architecture that made it possible. As governments call for leaner, more coordinated systems, a quieter question demands equal attention: who will still develop the medicines that markets will never find profitable? Product development partnerships have answered that question for nearly thirty years, delivering life-saving tools to billions who would otherwise remain invisible to pharmaceutical incentives. The challenge before the world now is not reform versus innovation, but the wisdom to pursue both without sacrificing either.
- Global health funding is tightening precisely as drug resistance accelerates and neglected diseases continue to claim lives in the world's poorest communities.
- The push for efficiency and coordination carries a hidden danger — a streamlined system can still fail to produce the medicines, vaccines, and diagnostics that people actually need.
- Product development partnerships have bridged this gap for nearly three decades, operating as nonprofit collaborators that absorb risks no commercial actor will take and prioritize public health over profit.
- Their results are concrete: over 79 health tools reaching 2.4 billion people, including a single-dose cure for sleeping sickness and the first antimalarial formulated for infants under five kilograms.
- As countries assert greater leadership over their own health systems, the partnership model must be embedded — not sidelined — within whatever reformed architecture emerges.
The global health system has accomplished something genuinely historic. Child mortality has fallen sharply. HIV, polio, and malaria have been pushed to the margins. But the machinery behind those victories is now under pressure — funding is contracting, donors are demanding efficiency, and calls for structural reform are growing louder. The danger is that a more organized system is not automatically a more effective one. Streamlining bureaucracy and empowering local leadership are worthy goals, but they do not, by themselves, produce new drugs. Drug-resistant pathogens are evolving. New diseases emerge. And millions of people in low-resource settings still cannot access the medicines that could save their lives.
One model has already demonstrated how innovation and reform can coexist. Product development partnerships bring together governments, researchers, pharmaceutical companies, academic institutions, and community groups around a shared principle: health innovation is a public good, not a profit center. When a disease is rare or its sufferers cannot pay, commercial actors have little incentive to act. PDPs fill that void, absorbing risks the market will not and prioritizing need over returns.
The results are not theoretical. Over nearly three decades, these partnerships have delivered more than seventy-nine health tools to two point four billion people — among them Acoziborole, a single-dose oral treatment for sleeping sickness that has transformed care in remote regions, and Coartem Baby, the first antimalarial formulated specifically for infants between two and five kilograms, a population that market-driven development had simply ignored.
What makes the model work is not only its nonprofit structure but the depth of its collaboration — engaging governments on national priorities, running trials in the communities carrying the heaviest disease burden, and ensuring that new products are usable where they are needed most. As the global health system reforms, this approach cannot be treated as peripheral. Without continued innovation, the gains of recent decades will erode. A country-led system is a worthy ambition — but it must still deliver the tools that keep people alive. The partnership model has already shown it can do both.
The global health system has achieved something remarkable. Child mortality has plummeted. HIV, polio, and malaria—diseases that once seemed unstoppable—have been pushed back. Yet the machinery that delivered these victories is now creaking under its own weight. Funding is tightening. Expectations are rising. Governments and donors are demanding something the current system cannot easily provide: efficiency, coordination, and an end to the waste that comes from fragmentation and duplication.
But there is a trap hidden in this demand for reform. A more organized system is not automatically a more effective one. You can streamline the bureaucracy, break down the silos, empower local leadership—and still fail to produce the tools that people actually need. Drug-resistant bacteria are evolving faster than we can respond. New pathogens emerge. And millions of people in the poorest parts of the world still cannot access the medicines, vaccines, and diagnostics that could save their lives. The real challenge is not choosing between reform and innovation. It is building a system that does both at once.
One model has already shown how this is possible. Product development partnerships—nonprofit organizations that bring together governments, researchers, pharmaceutical companies, academic institutions, philanthropies, and community groups—operate on a principle that traditional markets cannot: they treat health innovation as a public good rather than a profit center. When a disease is rare, or when the people who suffer from it cannot pay much, pharmaceutical companies have little incentive to develop treatments. The costs are high. The returns are uncertain. Governments often lack the resources or expertise to push a drug all the way through the development pipeline on their own. PDPs fill that gap. They can take risks that commercial actors will not. They can prioritize public health over shareholder returns.
The track record speaks for itself. Over nearly three decades, these partnerships have delivered more than seventy-nine health tools to two point four billion people. The beneficiaries are those least likely to benefit from market-driven medicine: children, newborns, pregnant women, and populations in low-resource settings. Acoziborole, a single-dose oral treatment for sleeping sickness developed through the Drugs for Neglected Diseases initiative, has transformed care for patients in remote areas where the disease still kills. Coartem Baby, created through a partnership between the Medicines for Malaria Venture and Novartis, is the first and only antimalarial drug formulated specifically for infants weighing between two and five kilograms—a population that traditional pharmaceutical development had simply overlooked.
These are not abstract victories. They are tools in the hands of real people in real places, solving problems that the profit motive had deemed unsolvable. What makes the partnership model work is not just the nonprofit structure, though that matters. It is the collaboration itself. PDPs engage with governments to understand national priorities. They conduct trials in the communities where the disease burden is highest. They work with the private sector, with researchers, with local health systems, to ensure that new products are not just scientifically sound but actually usable in the places where they are needed most. This is how country leadership becomes real—not through prescription from above, but through genuine partnership.
As the global health system undergoes its necessary reform, this model cannot be treated as optional. Without new medicines, new vaccines, and new diagnostics, the gains of the past decades will erode. Drug resistance will continue to spread. Neglected diseases will continue to kill. A country-led health system is a worthy goal. But it must still deliver the innovation that keeps people alive. The partnership approach has already proven it can do both. The question now is whether the reformed system will have the wisdom to strengthen what already works.
Citações Notáveis
PDPs close the gap between scientific possibility and real-world solutions by operating on a not-for-profit basis and prioritizing public health over market returns— Manica Balasegaram and Martin Fitchet
Without new medicines, vaccines, and diagnostics, today's gains will not be sustained, and tomorrow's needs will go unmet— Manica Balasegaram and Martin Fitchet
A Conversa do Hearth Outra perspectiva sobre a história
Why does the traditional pharmaceutical market fail so badly at treating diseases in poor countries?
Because there's no money in it. A company invests hundreds of millions to develop a drug, and if the people who need it most can't afford to buy it, the investment never pays back. So the market simply doesn't develop those medicines. It's not malice—it's how incentives work.
So product development partnerships solve this by removing the profit motive?
Not removing it entirely, but reordering it. They bring in governments, nonprofits, and philanthropies alongside pharmaceutical companies. The company still participates, but the goal is public health, not maximum returns. That changes what risks you're willing to take.
You mentioned sleeping sickness and infant malaria treatments. Are these common diseases?
No—that's the point. Sleeping sickness affects maybe ten thousand people a year in remote parts of Africa. Commercially, that's invisible. But for those ten thousand people and their communities, a single-dose cure is transformative. The partnership model makes room for that kind of specificity.
If PDPs have been around for thirty years and have reached billions of people, why isn't this the standard way we develop health tools?
Partly inertia. The traditional system is entrenched. Partly because partnerships are slower and more complex than pure market-driven development. And partly because donors and governments haven't always insisted on it. But as countries demand more control over their own health systems, the partnership model actually aligns with that shift. It's not top-down. It's collaborative.
What happens if we reform the global health system but don't keep innovation at the center?
You get a more efficient machine that produces fewer tools. Drug resistance spreads unchecked. Neglected diseases persist. The gains against child mortality start to reverse. You've organized the system beautifully, but it's organized around managing decline, not creating solutions.